| scholarly article | Q13442814 |
| P50 | author | W. Mark Saltzman | Q23092145 |
| P2093 | author name string | Ella R Hinson | |
| Peter Cresswell | |||
| Hong Shen | |||
| Richard L Edelson | |||
| Alessandra Giodini | |||
| Douglas J Hanlon | |||
| Virginia Cody | |||
| Anne L Ackerman | |||
| P2860 | cites work | The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules | Q28284349 |
| Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo | Q28595026 | ||
| Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor | Q29619247 | ||
| Cytoplasmic delivery of a macromolecular fluorescent probe by poly(d, l-lactic-co-glycolic acid) microspheres | Q30855750 | ||
| Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro | Q30869485 | ||
| Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo | Q31045989 | ||
| Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines | Q33683185 | ||
| Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen | Q33855119 | ||
| Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay | Q33903838 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| A new foreign policy: MHC class I molecules monitor the outside world | Q34398620 | ||
| Targeting vaccines to dendritic cells | Q34588561 | ||
| Biodegradable nanoparticles for drug and gene delivery to cells and tissue | Q35082117 | ||
| Vaccination of patients with solid tumours | Q35149453 | ||
| New tools for antigen delivery to the MHC class I pathway | Q35753113 | ||
| Cellular mechanisms governing cross-presentation of exogenous antigens | Q35821234 | ||
| Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens | Q35826361 | ||
| Part I: Vaccines for solid tumours | Q35937453 | ||
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma | Q36119828 | ||
| Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake | Q36367262 | ||
| Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines | Q36447615 | ||
| CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles | Q38555817 | ||
| Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. | Q38563231 | ||
| Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides | Q39340704 | ||
| CpG-DNA aided cross-priming by cross-presenting B cells | Q40597304 | ||
| Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. | Q40656615 | ||
| Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery | Q40713744 | ||
| Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells | Q40753335 | ||
| Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model | Q40964829 | ||
| Effects of cytokines on mycobacterial phagosome maturation | Q41043022 | ||
| Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules | Q41120866 | ||
| Intracellular transport of class I MHC molecules in antigen processing mutant cell lines | Q41522889 | ||
| Presentation of exogenous antigen with class I major histocompatibility complex molecules | Q41724565 | ||
| Defective presentation of endogenous antigen by a cell line expressing class I molecules | Q41736911 | ||
| Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. | Q43814408 | ||
| Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity | Q44078795 | ||
| Dendritic cell-based vaccination in solid cancer. | Q44265670 | ||
| Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro | Q44297910 | ||
| Protein encapsulation into biodegradable microspheres by a novel S/O/W emulsion method using poly(ethylene glycol) as a protein micronization adjuvant | Q44354994 | ||
| Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway | Q44473282 | ||
| Antigen loading of dendritic cells with whole tumor cell preparations | Q44473359 | ||
| Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles | Q44589782 | ||
| Differential transport requirements of HLA and H-2 class I glycoproteins | Q44765538 | ||
| Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells | Q45875123 | ||
| Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors | Q47409832 | ||
| Regulation of phagosome maturation by signals from toll-like receptors | Q47604798 | ||
| Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity | Q47628605 | ||
| Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems | Q48250150 | ||
| Transplantation of brain cells assembled around a programmable synthetic microenvironment | Q48769080 | ||
| Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules | Q50146397 | ||
| Delivery of tumor antigens to dendritic cells using biodegradable microspheres. | Q51570066 | ||
| pH-triggered microparticles for peptide vaccination. | Q51635616 | ||
| A novel microencapsulated peptide vaccine against hepatitis B. | Q52020177 | ||
| Rapid Peptide Turnover and Inefficient Presentation of Exogenous Antigen Critically Limit the Activation of Self-Reactive CTL by Dendritic Cells | Q58235001 | ||
| Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro | Q58867366 | ||
| A fluorometric assay for cholesterol reductase activity | Q67586883 | ||
| Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues | Q71527769 | ||
| Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles | Q73098451 | ||
| Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex | Q73168752 | ||
| Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody | Q73479961 | ||
| Release kinetics and immunogenicity of parvovirus microencapsulated in PLA/PLGA microspheres | Q73990836 | ||
| Fully mobilizing host defense: building better vaccines | Q77608031 | ||
| P433 | issue | 1 | |
| P921 | main subject | nanoparticle | Q61231 |
| biodegradation | Q696715 | ||
| P304 | page(s) | 78-88 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Immunology | Q15754984 |
| P1476 | title | Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles | |
| P478 | volume | 117 |
| Q38685236 | A Freeze-Concentration and Polyampholyte-Modified Liposome-Based Antigen-Delivery System for Effective Immunotherapy. |
| Q43784838 | A biodegradable and biocompatible drug-delivery system based on polyoxalate microparticles |
| Q35318315 | A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer |
| Q48511578 | A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma |
| Q38941777 | ANALYSIS OF DENDRITIC CELL STIMULATION UTILIZING A MULTI-FACETED NANOPOLYMER DELIVERY SYSTEM AND THE IMMUNE MODULATOR 1-METHYL TRYPTOPHAN. |
| Q36122915 | Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure. |
| Q26747586 | Adjuvants: Classification, Modus Operandi, and Licensing |
| Q91731105 | Advancements in Prophylactic and Therapeutic Nanovaccines |
| Q47848180 | An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis |
| Q43883594 | Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity |
| Q42863719 | Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation |
| Q33752783 | Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation |
| Q38838467 | Application of nanostructured drug delivery systems in immunotherapy of cancer: a review. |
| Q33894321 | Application of nanotechnologies for improved immune response against infectious diseases in the developing world |
| Q36591050 | Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases |
| Q34795079 | Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1. |
| Q37896455 | Bio-inspired, bioengineered and biomimetic drug delivery carriers |
| Q36502434 | Biodegradable particles as vaccine delivery systems: size matters |
| Q36978486 | Biodegradable polylactide microspheres enhance specific immune response induced by Hepatitis B surface antigen. |
| Q37483316 | Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation |
| Q35913715 | CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease |
| Q38288055 | Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking |
| Q34993838 | Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. |
| Q97883503 | Characterization of Bacillus anthracis Spore Proteins Using a Nanoscaffold Vaccine Platform |
| Q64250051 | Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant |
| Q39117175 | Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy |
| Q38680602 | Combinatorial drug delivery approaches for immunomodulation |
| Q42259049 | Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis |
| Q45357998 | Comparison of vaccine efficacy for different antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon (Salmo salar L.) in a cohabitation challenge model |
| Q36884768 | Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity |
| Q35667536 | Controlled Endolysosomal Release of Agents by pH-responsive Polymer Blend Particles |
| Q40730765 | Controlling influenza by cytotoxic T-cells: calling for help from destroyers |
| Q38737582 | Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses |
| Q29248618 | Current applications and future prospects of nanomaterials in tumor therapy |
| Q38746362 | Delivery systems for Leishmania vaccine development |
| Q39294119 | Dendritic cells in the host response to implanted materials |
| Q39849945 | Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination |
| Q50850972 | Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. |
| Q47137438 | Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens |
| Q34074750 | Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination |
| Q37062606 | Design opportunities for actively targeted nanoparticle vaccines |
| Q37744071 | Designing CD8+ T cell vaccines: it's not rocket science (yet). |
| Q37808118 | Designing polymeric particles for antigen delivery |
| Q37588454 | Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague |
| Q41662420 | Development of functionalized nanoparticles for vaccine delivery to dendritic cells: a mechanistic approach |
| Q36396099 | Diaminosulfide based polymer microparticles as cancer vaccine delivery systems |
| Q64116567 | Dual-Sized Microparticle System for Generating Suppressive Dendritic Cells Prevents and Reverses Type 1 Diabetes in the Nonobese Diabetic Mouse Model |
| Q84882761 | Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and β-glucan |
| Q89978286 | Effective Activation of Human Antigen-Presenting Cells and Cytotoxic CD8+ T Cells by a Calcium Phosphate-Based Nanoparticle Vaccine Delivery System |
| Q39161562 | Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles |
| Q47984619 | Electrospray Synthesis of Poly(lactide-co-glycolide) Nanoparticles Encapsulating Peptides to Enhance Proliferation of Antigen-Specific CD8+ T Cells |
| Q87612380 | Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a |
| Q57947036 | Endocytosis and intracellular processing of nanoparticles in dendritic cells: routes to effective immunonanomedicines |
| Q28085563 | Engineering New Approaches to Cancer Vaccines |
| Q96951726 | Engineering immunomodulatory biomaterials for type 1 diabetes |
| Q38154804 | Engineering synthetic vaccines using cues from natural immunity |
| Q34860928 | Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen |
| Q51132472 | Enhancement of antigen-specific CD4+ and CD8+ T cell responses using a self-assembled biologic nanolipoprotein particle vaccine. |
| Q38754451 | Evaluation of hydrophobic chitosan-based particulate formulations of porcine reproductive and respiratory syndrome virus vaccine candidate T cell antigens |
| Q30391225 | Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly |
| Q37591932 | Fabrication of nanoadjuvant with poly-ε-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity |
| Q35157029 | Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen |
| Q36212696 | Formulation and evaluation of oral microparticulate ovarian cancer vaccines |
| Q38757220 | Functionalization promotes pathogen-mimicking characteristics of polyanhydride nanoparticle adjuvants. |
| Q57227652 | Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants |
| Q64071651 | Harnessing Dendritic Cells for Poly (D,L-lactide--glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy |
| Q37354264 | Hepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response |
| Q34513978 | Improved antigen cross-presentation by polyethyleneimine-based nanoparticles |
| Q26766267 | Improving the clinical impact of biomaterials in cancer immunotherapy |
| Q35573167 | In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines. |
| Q35563449 | In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery |
| Q81083959 | Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine |
| Q36714925 | Induction of Potent Antigen-specific Cytotoxic T Cell Response by PLGA-nanoparticles Containing Antigen and TLR Agonist |
| Q92354318 | Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone |
| Q27309214 | Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity |
| Q35548034 | Induction of potent adaptive immunity by the novel polyion complex nanoparticles |
| Q37970755 | Interaction of nanoparticles with immunocompetent cells: nanosafety considerations |
| Q34785774 | Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy |
| Q38886698 | Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? |
| Q35740218 | Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responses |
| Q37812085 | Macrophage and dendritic cell phenotypic diversity in the context of biomaterials |
| Q39214943 | Mesoporous silica-calcium phosphate-tuberculin purified protein derivative composites as an effective adjuvant for cancer immunotherapy. |
| Q77791988 | Metal nanomaterials: immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease |
| Q38066148 | Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective |
| Q38073752 | Modern subunit vaccines: development, components, and research opportunities |
| Q37820820 | Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes |
| Q51068276 | Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy. |
| Q36452648 | Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody |
| Q37031671 | Nanocarrier-based immunotherapy in cancer management and research |
| Q48646732 | Nanomaterials for cancer immunotherapy. |
| Q38418305 | Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine. |
| Q36925868 | Nanomaterials in the application of tumor vaccines: advantages and disadvantages |
| Q58583890 | Nanoparticle Vaccines Against Infectious Diseases |
| Q35518723 | Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination |
| Q36269694 | Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy |
| Q50226473 | Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics |
| Q37279161 | Nanoparticle-based vaccine delivery for cancer immunotherapy |
| Q43623067 | Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice |
| Q26801067 | Nanotechnology: Future of Oncotherapy |
| Q34145500 | Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. |
| Q38341522 | Next generation vaccines: single-dose encapsulated vaccines for improved global immunisation coverage and efficacy |
| Q42248367 | Optimal conditions required for influenza A infection-enhanced cross-priming of CD8⁺ T cells specific to cell-associated antigens. |
| Q37463836 | PEGylated PLGA nanoparticles for the improved delivery of doxorubicin |
| Q38692217 | PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity |
| Q38793294 | PLGA-Listeriolysin O microspheres: Opening the gate for cytosolic delivery of cancer antigens |
| Q36897208 | PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival |
| Q39440275 | PLGA/PLA micro- and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.). |
| Q38114060 | Particle platforms for cancer immunotherapy |
| Q37860707 | Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines |
| Q50917304 | Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance. |
| Q33721852 | Poly(lactide-co-glycolide) nanoparticle assembly for highly efficient delivery of potent therapeutic agents from medical devices |
| Q41598583 | Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation. |
| Q34025136 | Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses. |
| Q37167802 | Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response |
| Q35709192 | Programming the composition of polymer blend particles for controlled immunity towards individual protein antigens |
| Q33928383 | Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells |
| Q84974580 | Quantitative Aspects of Intracellularly-Targeted Drug Delivery |
| Q27001699 | Recent advances in oral vaccine development: yeast-derived β-glucan particles |
| Q61813215 | Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles |
| Q38068954 | Recent progress towards development of a Shigella vaccine |
| Q30405708 | Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. |
| Q36966767 | Selectively targeting the toll-like receptor 9 (TLR9)--IRF 7 signaling pathway by polymer blend particles |
| Q42281935 | Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform. |
| Q28830111 | Self-assembly of polyphosphazene immunoadjuvant with poly(ethylene oxide) enables advanced nanoscale delivery modalities and regulated pH-dependent cellular membrane activity |
| Q33385557 | Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery |
| Q38583148 | Small Wonders-The Use of Nanoparticles for Delivering Antigen |
| Q39405264 | Spray-dried microparticles: a potential vehicle for oral delivery of vaccines |
| Q82592385 | Surface modification of poly(D,L‐lactic‐co‐glycolic acid) nanoparticles with protamine enhanced cross‐presentation of encapsulated ovalbumin by bone marrow‐derived dendritic cells |
| Q28085375 | Synthetic Nanoparticles for Vaccines and Immunotherapy |
| Q44997831 | TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses |
| Q37120117 | TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis |
| Q30869313 | Targeted delivery of vaccine to dendritic cells by chitosan nanoparticles conjugated with a targeting peptide ligand selected by phage display technique |
| Q34532116 | Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen |
| Q37082455 | The cell biology of cross-presentation and the role of dendritic cell subsets |
| Q43743678 | The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes |
| Q37327058 | The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells |
| Q38731626 | The uptake and intracellular fate of PLGA nanoparticles in epithelial cells |
| Q33383239 | Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein |
| Q40061497 | Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis |
| Q36712817 | Vaccine delivery using nanoparticles. |
Search more.